ALS patient lived with a brain-computer interface for 7 years. Here’s what researchers learned
Brain-computer interfaces are still years, and several FDA approvals, away from being available on the…
Category: als
Opinion: First Opinion readers respond to psychiatry and social contracts, Medicare and weight loss meds, and more
First Opinion is STAT’s platform for interesting, illuminating, and maybe even provocative articles about the…
Opinion: My stalled relay race to get access to ALS drugs in development
One night in November 2018, I fell while crossing a street in Subic Bay, a…
Opinion: Congress called for an ALS moonshot. The plan for it doesn’t leave Earth
The National Academies of Sciences, Engineering, and Medicine recently released a congressionally mandated report on…
STAT+: Watch: How Harvard researchers boosted an ALS patient’s independence with a box and a balloon
John Goodson practiced medicine for almost 50 years at Massachusetts General Hospital in Boston. As…
STAT+: Patient advocates clash over wisdom of ‘approving drugs faster and faster’
NEW YORK — Over 30 years ago, Gregg Gonsalves and other AIDS activists persuaded Congress…
Listen: A dilemma in ALS, the first MASH drug, & why gene therapy is hard
What happens when an approved drug doesn’t work? Why don’t patients want gene therapy? And…
After Amylyx ALS trial failure, patients share disappointment and fear — but some hope
The news last week that a Phase 3 trial of Amylyx Pharmaceuticals’ amyotrophic lateral sclerosis…
STAT+: Amylyx ALS drug failure leaves patients, advocates, and researchers reeling — and wondering what’s next
The latest disappointment in amyotrophic lateral sclerosis research brought crushing news for patients and physicians,…
STAT+: Insitro, biotech AI’s quiet unicorn, unveils efforts in ALS, liver disease, and cancer at JPM
New artificial intelligence technologies made headlines last year for their ability to do everything from…
STAT+: ALS patients support bill that could help patients with other rare diseases
WASHINGTON — A month after advisers to the Food and Drug Administration overwhelmingly voted against…
Listen: Live from the 2023 STAT Summit
What if CRISPR isn’t all that commercial? How does the NurOwn story end? And how…
STAT+: What we owe ALS patients — and why one company fell short
What do you say to a patient when the FDA rejects “their” experimental drug —…
STAT+: FDA advisers vote overwhelmingly against ALS treatment from BrainStorm
A panel of independent advisers to the Food and Drug Administration voted overwhelmingly against a…
STAT+: BrainStorm’s case for ALS approval relies on ‘grossly deficient’ data, FDA finds
The Food and Drug Administration said Monday that it has deep reservations about NurOwn, an…
A thorny ALS debate at the FDA, and the promise of artificial wombs
Can the FDA be too flexible? How do you test a mechanical womb? And who…
STAT+: They carry a gene for ALS but aren’t sick. What does medical research owe them?
Nine months after her mom died of ALS, Jean Swidler walked into a doctor’s office…
STAT+: What to know about the polarizing ALS drug headed for FDA scrutiny next week
Years of polarizing scientific discourse and bruising online debate will come to a head next…
What to Know About Late-Life Depression and the Challenges of Getting the Right Diagnosis
As you get older, you may find yourself becoming more relaxed and enjoying your grandchildren,…
STAT+: FDA approves new treatment from Biogen for rare form of ALS
The Food and Drug Administration on Tuesday granted conditional approval to a new treatment for…
STAT+: FDA advisory panel recommends conditional approval of Biogen’s drug for rare form of ALS
An independent panel of advisors to the Food and Drug Administration on Wednesday concluded that…
Illumina’s $8 billion limbo, a new treatment for ALS, & Emirati biotech funding
Is Illumina a victim of its own success? What makes the FDA change its mind?…
When spinal fluid from ALS patients was put into mice, the mice got weak. An unlikely protein could be the culprit
It was a shot in the dark — or at best, a dimly lit room:…
Listen: Private equity in autism care, a watershed FDA approval, and the future of ALS treatment
How did autism care become a big business? Can gene therapy be profitable? And whatever…
STAT+: Brainstorm to seek FDA approval for ALS stem-cell treatment, despite agency objections
Last year, the Food and Drug Administration issued a rare public statement to inform the…
Irisin May Have a Future as Treatment to Reduce Brain Inflammation, Preserve Memory
The protective benefits of regular exercise on cognition are well established, but researchers are still…
STAT+: Biogen drug for rare form of ALS fails pivotal study — another setback for fatal disease with few treatments
Biogen reported disappointing results Sunday from a late-stage clinical trial involving its experimental treatment for…
STAT+: Brainstorm’s cell therapy for ALS fails study, but company sees signs of efficacy — and may push for approval
Brainstorm Cell Therapeutics reported disappointing results Tuesday from a late-stage clinical trial involving its experimental…
Ask Doctor Etingin: Causes of blurry vision … ALS … Body weight and Alzheimer’s disease risk
Q: What causes blurry vision? A: Blurry vision can be caused by a refractive error,…